Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors

Journal of Neuro-Oncology

Volumn 118, Issue 2, 2014, Pages 225-238

  Samuel, Nardin ^a,b   Remke, Marc ^b   Rutka, James T ^a,b   Raught, Brian ^a   Malkin, David ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomarker; Cerebrospinal fluid (CSF); Neuro oncolgy; Pediatric; Proteomics

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN A2; CYCLOPHILIN A; HEMORPHIN 7; L SELECTIN; NERVE CELL ADHESION MOLECULE; OSTEOPONTIN; PROSTAGLANDIN D2 SYNTHASE; SOMATOMEDIN BINDING PROTEIN 3; TAU PROTEIN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

BRAIN BIOPSY; BRAIN TUMOR; CANCER CLASSIFICATION; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; DIAGNOSTIC ACCURACY; DISEASE MARKER; GERM CELL TUMOR; GLIOMA; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; MOLECULAR DIAGNOSIS; NONHUMAN; ONSET AGE; PRIMARY TUMOR; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SOLID TUMOR; ANIMAL; CEREBROSPINAL FLUID; PROCEDURES;

ANIMALS; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CHILD; HUMANS; PROTEOMICS;

EID: 84903894377     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1432-3     Document Type: Review

References (66)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER web site, December 2013
2. Astrakas LG, Zurakowski D, Tzika AA, Zarifi MK, Anthony DC, Girolami UD, Tarbell NJ, Black PM (2004) Noninvasive magnetic resonance spectroscoping imaging biomarkers to predict the clinical grade of pediatric brain tumors. Clin Cancer Res 10:8220
3. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971-983
4. van Dijk KD, Teunissen CE, Drukarch B, Jimenez CR, Groenewegen HJ, Berendse HW, van de Berg WD (2010) Diagnostic cerebrospinal fluid biomarkers for Parkin's disease: a pathogenetically based approach. Neurobiol Dis 39(3):229-241
5. Nishizaki T, Kajiwara K, Adachi N, Tsuha M, Nakayama H, Ohshita N, Ikeda N, Ito H, Suzuki M (2001) Detection of craniospinal dissemination of intracranial germ cell tumors based on serum and cerebrospinal fluid levels of tumor markers. J Clin Neurosci 8(1):27-30
6. Seregni E, Massimino M, Nerini Molteni S, Pallotti F, van der Hiel B, Cefalo G, Spreafico F, Fossati F, Bombardieri E (2002) Serum and cerebrospinal fluid human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) in intracranial germ cell tumors. Int J Biol Markers 17(2):112-118
7. Legault G, Allen JC (2013) Potential role of ventricular tumor markers in CNS germ cell tumors. Pediatr Blood Cancer 60(10):1647-1650. doi: 10.1002/pbc.24620
8. Ispas CR, Crivat G, Andreescu S (2012) Review: recent developments in enzyme-based biosensors for biomedical analysis. Anal Letts 45(168):186
9. Sigdel TK, Gao X, Sarwal MM (2012) Protein and peptide biomarkers in organ transplantation. Biomark Med 6(3):259. doi: 10.2217/bmm.12.29
10. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3):131-144. doi: 10.1038/nrneurol.2010.4
11. Parnetti L, Castrioto A, Chiassernini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P (2013) Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 9(3):131-140. doi: 10.1038/nrneurol.2013.10
12. Allen J, Chacko J, Donahue B, Dhall G, Kretschmar C, Jakacki R, Holmes E, Pollack I (2012) Diagnostic sensitivity of serum and lumbar CSF bHCG in newly diagnosed CNS germinoma. Pediatr Blood Cancer 59(7):1180-1182. doi: 10.1002/pbc.24097
13. Watanabe S, Aihara Y, Kikuno A, Sato T, Komoda T, Kubo O, Amano K, Okada Y, Koyamaishi Y (2012) A highly sensitive and specific chemiluminescent enzyme immunoassay for placental alkaline phosphatase in the cerebrospinal fluid of patients with intracranial germinomas. Pediatr Neurosurg 48(3):141-145. doi: 10.1159/000345632
14. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, Chan DW, Canto M, Lillemoe KD, Cameron JL, Yeo CJ, Hruban RH, Goggins M (2002) Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 62(6):1868-1875
15. Begcevic I, Kosanam H, Martinez-Morillio E, Dimitromanolaskis A, Diamandis P, Kuzmanov U, Hazrati LN, Diamandis EP (2013) Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brain. Clin Proteomics 10(1):5. doi: 10.1186/1559-0275-10-5
16. Saratsis AM, Kambhampati M, Snyder K, Yadavilli S, Devaney JM, Harmon B, Hall J, Raabe EH, An P, Weingart M, Rood BR, Magge SN, Macdonald TJ, Packer RJ, Nazarian J (2013) Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathol [Epub ahead of print]
17. Whitin JC, Jang T, Merchant M, Yu TT, Lau K, Recht B, Cohen HJ, Recht L (2012) Alterations in cerebrospinal fluid proteins in a presymptomatic primary glioma model. PLoS ONE 7(11):e49724. doi: 10.1371/journal.pone.0049724
18. Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J, Van Meir EG, Ritchie JC, Brat DJ (2006) Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 6(23):6277-6287
19. Weisher B, Bernheardt W (1978) Protein fractions of lumbar cisternal and ventribular cerebrospinal fluid. Separate areas of reference. J Neurol Sci 37:205-214
20. Thompson EJ, Keir G (1990) Laboratory investigation of cerebrospinal fluid proteins. Ann Clin Biochem 5:425-435
21. Stoop MP, Coulier L, Rosenling T, Shi S, Smolinska AM, Buydens L, Ampt K, Stingl C, Dane A, Muliwiik B, Luitwieler RL, Sillevis Smith PA, Hintzen RQ, Bischoff R, Wimenga SS, Hankemeier T, van Gool AJ, Luider TM (2010) Mol Cell Proteomics 9(9): 2063-2075. doi: 10.1074/mcp.M900877-MCP200
22. Waybright T, Avellino AM, Ellenbogen RG, Hollinger BJ, Veenstra TD, Morrison RS (2010) Characterization of the human ventricular cerebrospinal fluid proteome obtained from hydrocephalus patients. J Proteomics 73(6):1156-1162. doi: 10.1016/j.jprot.2010.02.004
23. Römpp A, Dekker L, Taban I, Jenster G, Boogerd W, Bonfrer H, Spengler B, Heeren R, Smitt PS, Luider TM (2007) Identification of leptomeningeal metastasis-related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nanoLC-FTICR MS. Proteomics 7(3):474-481
24. Brandsma D, Voest EE, de Jager W, Bonfrer H, Algra A, Boogerd W, Korse T, Reijneveld JC, Verbeek MM, Rijkers G, Taphoorn MJ (2006) CSF protein profiling using multiplex immuno-assay: a potential new diagnostic tool for leptomeningeal metastatses. J Neurol 253(9):1177-1184
25. Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA (2013) A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA Neurol 70(3):311-319. doi: 10.1001/jamaneurol.2013.606
26. Tang YT, Jiang F, Guo L, Si MY, Jiao XY (2013) The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis. J Neurooncol 112(3):329-338. doi: 10.1007/s11060-013-1066-x
27. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Schuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL (2008) Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 26(1):96-105
28. Zheng PP, Luider TM, Pieters R, Avezaat CJ, van den Bent MJ, Sillevis Smitt PA, Kros JM (2003) Identification of tumor-related protein by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 62(8):855-862
29. Kim JH, Lee SK, Yoo YC, Park NH, Park DB, Yoo JS, An HJ, Park YM, Cho KG (2012) Proteome analysis of human cerebrospinal fluid as a diagnostic biomarker in patients with meningioma. Med Sci Monit 18(11):450-460
30. Peles E, Lidar Z, Simon AJ, Grossman R, Nass D, Ram Z (2004) Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery 55(3):562-567
31. Khwaja FW, Reed MS, Olson JJ, Scmotzer BJ, Gillespie GY, Guha A, Groves MD, Kesari S, Pohl K, Van Meri EG (2007) Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 6(2):559-570
32. Schuhmann MU, Zucht HD, Nassimi R, Heine G, Schneekloth CG, Stuerenburg HJ, Selle H (2010) Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol 36(2):201-207. doi: 10.1016/j.ejso.2009.07.010
33. Ohnishi M, Matsumoto T, Nagashio R, Kageyama T, Utsuki S, Oka H, Okayasu I, Sato Y (2009) Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein. Pathol Int 59(11):797-803. doi: 10.1111/j.1440-1827.2009.02447.x
34. Zhu W, Smith JW, Huang CM (2010) Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol 2010:840518. doi: 10.1155/2010/840518
35. Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ, Berven FS (2011) Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics 74(4):371-388. doi: 10.1016/j.jprot.2010.11.010
36. Paweletz CP, Wiener MC, Bondarenko AY, Yates NA, Song Q, Liaw A, Lee AY, Hunt BT, Henle ES, Meng F, Sleph HF, Holahan M, Sanaranarayanan S, Simon AJ, Settlage RE, Sachs JR, Shearman M, Sachs AB, Cook JJ, Hendrickson RC (2010) Application of an end-to-end biomarker discovery platform to identify target engagement biomarkers in cerebrospinal fluid by high resolution differential mass spectrometry. J Proteome Res 9(3):1392-1401. doi: 10.1021/pr900925d
37. Blonder J, Issaq HI, Veenstra TD (2011) Proteomic biomarker discovery: it's more than just mass spectrometry. Electrophoresis 32(13):1541-1548. doi: 10.1002/elps.201000585
38. Rajagopal MU, Hathout Y, MacDonald TJ, Kieran MW, Gururangan S, Blaney SM, Phillips P, Packer R, Gordish-Dressman H, Rood BR (2011) Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: a pediatric brain tumor consortium study. Proteomics 11(5):935-943. doi: 10.1002/pmic.201000198
39. Saratsis AM, Yadavilli S, Magge S, Rood BR, Perez J, Hill DA, Hwang E, Kilburn L, Packer RJ, Nazarian J (2012) Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid. Neuro Oncol 14(5):547-560. doi: 10.1093/neuonc/nos067
40. Desiderio C, D'Angelo L, Rossetti DV, Iavarone F, Giardina B, Castagnola M, Massimi L, Tamburrini G, Di Rocco C (2012) Cerebrospinal fluid top-down proteomics evidenced the potential biomarker role of LVV- and VV-hemorphin-7 in posterior cranial fossa pediatric brain tumors. Proteomics 12(13):2158-2166. doi: 10.1002/pmic.201100499
41. Saso L, Leone MG, Sorrentino C, Giacomelli S, Silvestrini B, Grima J, Li JC, Samy E, Mruk D, Cheng CY (1998) Quantification of prostaglandin D synthetase in cerebrospinal fluid: a potential biomarker for brain tumor. Biochem Mol Biol Int 46(4):643-656
42. Huang YC, Lyu RK, Tseng MY, Chang HS, Hsu WC, Kuo HC, Chu CC, Wu YR, Ro LS, Huang CC, Chen CM (2009) Decreased intrathecal synthesis of prostaglandin D2 synthase in the cerebrospinal fluid of patients with acute inflammatory demyelinating polyneuropathy. J Neuroimmunol 206(1-2):100-105. doi: 10.1016/j.jneuroim.2008.10.011
43. de Bont JM, Vanderstichele H, Reddingius RE, Pieters R, van Gool SW (2008) Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients. Eur J Paediatr Neurol 12(4):334-341
44. Walker DA, Punt JA, Sokal M (1999) Clinical management of brain stem glioma. Arch Dis Child 80(6):558-564
45. Leach PA, Estilin EJ, Coope DJ, Thorne JA, Kamaly-Asl ID (2008) Diffuse brainstem gliomas in children: should we or shouldn't we biopsy? Br J Neurosurg 22(5):619-624. doi: 10.1080/02688690802366198
46. Zagzag D, Miller DC, Knopp E, Farmer JP, Lee M, Biria S, Pellicer A, Epstein FJ, Allen JC (2000) Primitive neuroectodermal tumors of the brainstem: investigation of seven cases. Pediatrics 106(5):1045-1053
47. Rutka JT (2012) Biopsy of diffuse intrinsic pontine gliomas? J Neurosurg Pediatr 10(2):79-80. doi: 10.3171/2012.2.PEDS1237
48. Fuzéry AK, Levin J, Chan MM, Chang DW (2013) Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 10(1):13. doi: 10.1186/1559-0275-10-13
49. Russell MD, Young AMH, Karri SK (2013) Biomarkers of pediatric brain tumors. Front Pediatr 1(7):1-7. doi: 10.3389/fped.2013.00007
50. Waybright TJ (2013) Preparation of human cerebrospinal fluid for proteomics barker analysis. Methods Mol Biol 1002:61-70. doi: 10.1007/978-1-62703-360-2-5
51. Petzold A (2006) Sharpe LT, Keir G (2006) Spectrophotometry for cerebrospinal fluid pigment analysis. Neurocrit Care 4:153-162
52. Berven FS, Kroksveen AC, Berle M, Rajalahti T, Flikka K, Arneberg R, Myhr KM, Vedeler C, Kvalheim OM, Ulvik RJ (2007) Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin Appl 1(7):699-711. doi: 10.1002/prca.200700126
53. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73(22):1914-1922. doi: 10.1212/WNL. 0b013e318c47cc2
54. Carrette O, Burkhard PR, Hughes S, Hochstrasser DF, Sanchez JC (2005) Truncated cystatin C in cerebrospinal fluid: technical artifact or biological process? Proteomics 5:3060-3065
55. Hebert AS, Richards AL, Bailey DJ, Ulbrich A, Coughlin EE, Westphall MS, Coon JJ (2014) The one hour yeast proteome. Mol Cell Protemoics 13(1):339-347. doi: 10.1074/mcp.M113.034769
56. Butcher EC, Berg EL, Kunkel EJ (2004) Systems biology in drug discovery. Nat Biotechnol 22(10):1253-1259
57. de Bont JM, den Boer ML, Reddingius RE, Jansen J, Passier M, van Schaik RH, Kros JM, Sillevis Smtt PA, Luider TH, Pieters R (2006) Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling. Clin Chem 52(8):1501-1509
58. Müller HL, Oh Y, Lehrnbecher T, Blum WF, Rosenfeld RG (1994) Insulin-like growth factor-binding protein 2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 79(2):428-434
59. Müller HL, Oh Y, Gargosky SE, Lehrnbecher T, Hintz RL, Rosenfeld RG (1993) Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis. J Clin Endorcinol Metab 77(5):1113-1119
60. de Bont JM, van Doorn J, Reddingius RE, Graat GH, Passier MM, den Boer ML, Pieters R (2008) Various components of the insulin-like growth factor system in tumor tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients. Int J Cancer 123(3):594-600. doi: 10.1002/ijc.23558
61. Kao CL, Chiou SH, Ho DM, Chen YJ, Liu RS, Lo CW, Tsai FT, Lin CH, Ku HH, Yu SM, Wong TT (2005) Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor. Am J Clin Pathol 123(2):297-304
62. Incesoy-Özdemir S, Sahin G, Bozkurt C, Oren AC, Balkaya E, Ertem U (2013) The relationship between cerebrospinal fluid osteopontin level and central nervous system involvement in childhood acute leukemia. Turk J Pediatr 55(1):42-49
63. Figarelle-Branger D, Dubois C, Chauvin P, De Victor B, Gentet JC, Rougon G (1996) Correlation between polysialtic-neural cell adhesion molecule levels in CSF and medulloblastoma outcomes. J Clin Oncol 14(7):2066-2072
64. Ishii E, Ohga S, Murano I, Kobayashi M, Kimura K, Eguchi H, Akazawa K, Ueda K (1991) Tumor necrosis factor in the cerebrospinal fluid of children with central nervous system leukemia. Leuk Res 15(2-3):143-147
65. Miyanohara O, Takeshima H, Kaji M, Hirano H, Sawamura Y, Kochi M, Kurastu J (2002) Diagnostic significance of soluble c-kit in the cerebrospinal fluid of patients with germ cell tumors. J Neurosurg 97(1):177-183
66. Dagdemir A, Ertem U, Duru F, Kirazli S (1998) Soluble L-selectin increases in the cerebrospinal fluid prior to meningeal involvement in children with acute lymphoblastic leukemia. Leuk Lymphoma 28(3-4):391-398